Alzheimer's therapy enters phase IIa clinical trial

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

New York City-based Anavex Life Sciences has developed an investigational treatment for Alzheimer's called Anavex 2-73, and announced Nov. 7 that the company would be working with Neuronetrix to take the drug through a phase IIa clinical trial.

Key research components will be conducted by Louisville-based Neuronetrix, chosen due to the latter's proprietary neuro-electrophysiological technology used to evaluate cognitive function.

The trial will include the study of multiple biomarkers and their effect on cognition in 32 patients with mild to moderate Alzheimer's disease. It is scheduled to take place in up to seven research centers in Australia over six months.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.